Study summary

An amylin and GLP-1 combination cut weight by 13.7% in type 2 diabetes

REDEFINE 2 trial (CagriSema) · 1,206 people, phase 3 · Published June 2025, New England Journal of Medicine

13.7%weight loss, vs 3.4% with placebo

What was tested

Weekly cagrilintide plus semaglutide (CagriSema) against placebo for 68 weeks in adults with type 2 diabetes and overweight or obesity.

What they found

What it means

Amylin-based drugs are a growing class in diabetes and obesity.

N Engl J Med, via PubMed ↗ Trial record NCT05394519 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.